Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of AK002 in active eosinophilic esophagitis
2019-004391-19Phase 2Completed
- Sponsor
- Allakos Inc.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing AK002 with Placebo (2 arms). Primary endpoint: Histologic remission at Week 24. Started May 2020; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2019-004391-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004391-19.